This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): etanercept
Description: Enbrel is a recombinant protein with properties of a monoclonal antibody. It is a fusion protein of the Fc (constant region) of a human antibody grafted to the ligand-binding portion of the human TNF receptor. The TNF receptor part of Enbrel functionally substitutes for an anti-TNF antibody. Because of this construction, Enbrel is similar to anti-TNF monoclonal antibodies, including Johnson & Johnson’s Remicade and Abbott’s Humira (D2E7).
Blocking the activity of TNF impacts both autoimmunity and the immune response to pathogens. Much of Enbrel’s risk/benefit profile is a trade-off between these influences.
Amgen and Wyeth
Immunex (now a subsidiary of Amgen) and American Home Products (now called Wyeth) partnered in September 1997 to promote Enbrel in North America for all non-oncological indications. Amgen and AHP jointly market Enbrel in the U.S. Amgen receives approximately 55% of the gross profits.
Takeda and Wyeth
Takeda and Wyeth co-promote Enbrel in Japan through their joint venture Wyeth K.K.
Pfizer and Wyeth
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The acquisition was completed in October 2009.
Pfizer and Amgen
In October 2013, Pfizer reported that their US and Canadian co-promotional agreement for Enbrel with Amgen has expired. However, their exclusive rights to Enbrel outside of the US and Canada are not affected. Amgen now...See full deal structure in Biomedtracker
Partners: Pfizer Inc. GlaxoSmithKline plc DRI Capital Inc.
Pink Sheet Erelzi Clinical Development Timeline
Additional information available to subscribers only: